S292: SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL

• N. Cooper,
• W. Ghanima,
• N. Vianelli,
• D. Valcárcel,
• I. Yavaşoğlu,
• A. Melikyan,
• E. Yañez Ruiz,
• J. Haenig,
• J. Lee,
• J. Maier,
• N. Zolkin,
• F. Zaja

Affiliations

N. Cooper

1 Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, United Kingdom

W. Ghanima

2 Department of Medicine, Østfold Hospital Trust, Kalnes, Norway

N. Vianelli

3 Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

D. Valcárcel

4 Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Spain

I. Yavaşoğlu

5 Department of Hematology, Adnan Menderes University, Aydin, Turkey

A. Melikyan

6 National Research Center for Hematology, Moscow, Russia

E. Yañez Ruiz

7 Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Temuco, Chile

J. Haenig

8 Novartis Pharma AG, Basel, Switzerland

J. Lee

9 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States of America

J. Maier

8 Novartis Pharma AG, Basel, Switzerland

N. Zolkin

10 IQVIA, St. Petersburg, Russia

F. Zaja

11 Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy